Aclarion (ACON) Competitors $6.84 -0.04 (-0.51%) As of 11:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ACON vs. BRTX, MGRX, OTRK, SSY, BGLC, DHAC, ATIP, VSEE, NIVF, and BACKShould you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include BioRestorative Therapies (BRTX), Mangoceuticals (MGRX), Ontrak (OTRK), SunLink Health Systems (SSY), BioNexus Gene Lab (BGLC), Digital Health Acquisition (DHAC), ATI Physical Therapy (ATIP), Vsee Health (VSEE), NewGenIvf Group (NIVF), and IMAC (BACK). These companies are all part of the "healthcare" industry. Aclarion vs. BioRestorative Therapies Mangoceuticals Ontrak SunLink Health Systems BioNexus Gene Lab Digital Health Acquisition ATI Physical Therapy Vsee Health NewGenIvf Group IMAC Aclarion (NASDAQ:ACON) and BioRestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends. Does the MarketBeat Community prefer ACON or BRTX? Aclarion received 2 more outperform votes than BioRestorative Therapies when rated by MarketBeat users. However, 100.00% of users gave BioRestorative Therapies an outperform vote while only 80.00% of users gave Aclarion an outperform vote. CompanyUnderperformOutperformAclarionOutperform Votes480.00% Underperform Votes120.00% BioRestorative TherapiesOutperform Votes2100.00% Underperform VotesNo Votes Do institutionals & insiders have more ownership in ACON or BRTX? 7.5% of Aclarion shares are owned by institutional investors. Comparatively, 69.4% of BioRestorative Therapies shares are owned by institutional investors. 0.8% of Aclarion shares are owned by company insiders. Comparatively, 25.5% of BioRestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to ACON or BRTX? In the previous week, BioRestorative Therapies had 2 more articles in the media than Aclarion. MarketBeat recorded 5 mentions for BioRestorative Therapies and 3 mentions for Aclarion. Aclarion's average media sentiment score of 1.00 beat BioRestorative Therapies' score of -0.67 indicating that Aclarion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclarion 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioRestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Which has preferable earnings & valuation, ACON or BRTX? Aclarion has higher earnings, but lower revenue than BioRestorative Therapies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclarion$45.72K87.00-$4.91MN/AN/ABioRestorative Therapies$401K29.66-$14.41M-$1.47-1.08 Do analysts prefer ACON or BRTX? Aclarion currently has a consensus price target of $11,758.50, suggesting a potential upside of 171,933.65%. BioRestorative Therapies has a consensus price target of $18.00, suggesting a potential upside of 1,035.65%. Given Aclarion's higher probable upside, equities analysts clearly believe Aclarion is more favorable than BioRestorative Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50BioRestorative Therapies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ACON or BRTX more profitable? BioRestorative Therapies has a net margin of -2,697.08% compared to Aclarion's net margin of -12,845.05%. BioRestorative Therapies' return on equity of -98.49% beat Aclarion's return on equity.Company Net Margins Return on Equity Return on Assets Aclarion-12,845.05% -422.87% -201.15% BioRestorative Therapies -2,697.08%-98.49%-75.23% Which has more volatility & risk, ACON or BRTX? Aclarion has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 77.73, indicating that its share price is 7,673% more volatile than the S&P 500. SummaryBioRestorative Therapies beats Aclarion on 10 of the 15 factors compared between the two stocks. Get Aclarion News Delivered to You Automatically Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACON vs. The Competition Export to ExcelMetricAclarionMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.98M$2.90B$5.31B$8.42BDividend YieldN/A31.23%5.21%4.10%P/E RatioN/A12.7526.7819.69Price / Sales87.00158.13386.97118.34Price / CashN/A57.5638.2534.62Price / Book-0.054.256.744.50Net Income-$4.91M-$22.21M$3.23B$248.32M7 Day Performance-0.94%1.64%1.49%-0.03%1 Month Performance-8.99%1.98%11.47%12.72%1 Year Performance-99.77%1.21%16.57%7.38% Aclarion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACONAclarion1.6392 of 5 stars$6.84-0.5%$11,758.50+171,933.7%-99.8%$3.98M$45,724.000.007Positive NewsEarnings ReportBRTXBioRestorative Therapies3.3258 of 5 stars$1.59-1.6%$18.00+1,035.6%+23.0%$11.90M$401,000.00-1.047Analyst RevisionGap DownMGRXMangoceuticals0.1827 of 5 stars$1.51+2.4%N/A-98.7%$7.78M$615,873.00-0.263Earnings ReportOTRKOntrak2.5265 of 5 stars$1.58+1.9%$45.00+2,748.1%-61.2%$6.66M$10.85M-0.15250News CoverageEarnings ReportGap UpSSYSunLink Health SystemsN/A$0.86+4.1%N/A+42.5%$6.06M$31.23M6.141,376News CoverageAnalyst ForecastGap UpBGLCBioNexus Gene Lab0.2595 of 5 stars$2.69-5.6%N/A-44.9%$4.83M$9.51M0.0030Negative NewsEarnings ReportDHACDigital Health AcquisitionN/A$1.11+1.5%N/A-91.4%$4MN/A0.002,021ATIPATI Physical TherapyN/A$0.90flatN/A-81.3%$3.97M$741.86M-0.055,600VSEEVsee Health1.1856 of 5 stars$1.08-2.6%$5.00+362.5%N/A$3.90M$6.38M0.00N/AGap UpNIVFNewGenIvf Group1.0068 of 5 stars$3.23+9.5%N/A-98.9%$1.70M$5.43M0.00N/AHigh Trading VolumeBACKIMACN/A$0.04+15.2%N/A-99.1%$75,000.00$72,050.000.00180 Related Companies and Tools Related Companies BioRestorative Therapies Competitors Mangoceuticals Competitors Ontrak Competitors SunLink Health Systems Competitors BioNexus Gene Lab Competitors Digital Health Acquisition Competitors ATI Physical Therapy Competitors Vsee Health Competitors NewGenIvf Group Competitors IMAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACON) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACON Stock Free ACON Stock Alerts